The Molecular Pharmacology Shared Resource (MPSR) provides a mechanism for high-quality collection, processing and analysis of clinical specimens for pharmacokinetic and correlative studies from clinical trial patients. Additionally, this resource conducts preclinical modeling of novel anticancer agents and therapeutic combinations to explore promising avenues for clinical trial design. The resource participates in all levels of our clinical trials program, from preclinical study rationale, protocol development, novel assay development, specimen collection, correlative analysis of patient material, data analysis and publication. The MPSR offers the following categories of services for our investigators: 1) Specimen Collection: The MPSR oversees blood and other surrogate cell collection for patients enrolled on clinical trials conducted at UCDCCC. This service is utilized by clinical investigators executing clinical trials that include a specimen collection component. Virtually all research blood collection conducted at our Cancer Center on clinical trials patients is overseen by the MPSR, regardless of its complexity. The MPSR has substantial specialized specimen collection and processing capabilities, particularly for pharmacokinetic and pharmacodynamic analysis. This HIPAA-compliant resource meets or exceeds all University, local, state and federal regulations necessary for these services. 2) Correlative Studies: The MPSR is particularly vested in the identification and validation of biomarkers and molecular signatures predictive of patient outcome. In addition to CLIA-certified biomarker testing conducted jointly with the UC Davis Molecular Diagnostics Laboratories utilized in Phase II and III studies, we focus on investigational/developmental assays typically performed in conjunction with our early phase clinical trial program. The MPSR conducts analysis and research at our labs on the Sacramento campus or partners with outside labs or commercial entities. In either scenario, the MPSR is responsible for specimen shipping, tracking and anonymization, and is the recipient of the data generated. 3) Preclinical Modeling: The Shared Resource also conducts preclinical modeling and translational research with clinical impact, and works with UCDCCC investigators to establish and test strategies in the laboratory for personalized medicine that are translatable to the clinic. In addition to a variety of cell line- and traditional xenograft-based analyses, the MPSR functions as a link between clinical investigators at UCD and our colleagues at The Jackson Laboratory (JAX) for studies involving patient-derived xenografts (PDXs). The MPSR is by far the biggest user at UCDCCC of the JAX PDX modeling system and has played an integral role in the development of this resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA093373-16S1
Application #
9773707
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lin, Alison J
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
16
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Turner, David C; Kondic, Anna G; Anderson, Keaven M et al. (2018) Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res 24:5841-5849
Matsumoto, Collin; Jiang, Yan; Emathinger, Jacqueline et al. (2018) Short Telomeres Induce p53 and Autophagy and Modulate Age-Associated Changes in Cardiac Progenitor Cell Fate. Stem Cells 36:868-880
Gandara, David R; Riess, Jonathan W; Lara Jr, Primo N (2018) In Search of an Oncogene Driver for Squamous Lung Cancer. JAMA Oncol 4:1197-1198
Long, Qilai; Lin, Tzu-Yin; Huang, Yee et al. (2018) Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine 14:789-799
Withers, Sita S; Moore, Peter F; Chang, Hong et al. (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. Dev Comp Immunol 87:64-74
Riess, Jonathan W; Gandara, David R; Frampton, Garrett M et al. (2018) Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol 13:1560-1568
Rowson-Hodel, A R; Wald, J H; Hatakeyama, J et al. (2018) Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene 37:197-207
Zhang, Jin; Xu, Enshun; Ren, Cong et al. (2018) Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN. Cancer Res 78:1511-1521
Wang, Minan; Yao, Li-Chin; Cheng, Mingshan et al. (2018) Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J 32:1537-1549
York, D; Sproul, C D; Chikere, N et al. (2018) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol 16:102-107

Showing the most recent 10 out of 836 publications